ClinicalTrials.gov posted results on 21 September 2026 for a Phase II trial comparing pembrolizumab every 12 weeks with every 3 weeks in non-small cell lung cancer (NSCLC). The study enrolled 9 participants; the posted 1-year progression-free survival counts were 4 participants in the 3-week arm and 2 participants in the 12-week arm.
Background
The trial studied pembrolizumab in patients with lung non-small cell carcinoma. Its registry summary describes pembrolizumab as a monoclonal antibody used in immunotherapy that may help the immune system attack cancer and interfere with tumor-cell growth and spread. The study asked whether dosing every 12 weeks could provide similar disease control to dosing every 3 weeks with fewer treatments. The supplied record does not provide information about prior approvals or disease prevalence.
Trial design
This Phase II trial, identified as NCT04032418, enrolled 9 participants and is listed as active, not recruiting. It compared pembrolizumab given every 3 weeks with pembrolizumab given every 12 weeks. The record lists no primary-outcome entries, and the supplied data do not specify a primary endpoint or provide details about randomization. Posted measurements included 1-year progression-free survival, overall survival, and incidence of adverse events.
Key results
At 1 year, the registry reported progression-free survival counts of 4 participants in the 3-week arm and 2 participants in the 12-week arm. Median overall survival was 21.38809 months with 3-week dosing and 46.91581 months with 12-week dosing. The record labels a 95% confidence interval for these median estimates but supplies no interval values. The listed incidence-of-adverse-events count was 0 participants in each arm. No p-values or comparative analyses were supplied.
What this means
These registry measurements describe outcomes in a very small study and do not establish that one dosing schedule is more effective than the other. The reported counts and median survival estimates should be interpreted cautiously: the supplied data do not include a numerical confidence interval, statistical comparisons, or primary-outcome entries. The zero adverse-event counts are the values posted for this measure, but the record provided here does not give further detail on adverse-event collection or reporting.
Source
Source: ClinicalTrials.gov, registry results for “Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer,” posted 21 September 2026. Available at clinicaltrials.gov/study/NCT04032418.